Ac-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application
The application of <sup>225</sup>Ac (half-life T<sub>1/2</sub> = 9.92 d) dramatically reduces the activity used for peptide receptor radionuclide therapy by a factor of 1000 in comparison to <sup>90</sup>Y, <sup>177</sup>Lu or <sup>188</sup>...
Main Authors: | Marc Pretze, Falk Kunkel, Roswitha Runge, Robert Freudenberg, Anja Braune, Holger Hartmann, Uwe Schwarz, Claudia Brogsitter, Jörg Kotzerke |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/7/652 |
Similar Items
-
Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01) -
Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report
by: Letjie C. Maserumule, et al.
Published: (2021-03-01) -
Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study
by: Sui wai Ling, et al.
Published: (2024-01-01) -
Design of a Thorium Metal Target for <sup>225</sup>Ac Production at TRIUMF
by: Andrew K.H. Robertson, et al.
Published: (2019-02-01) -
Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)